↓ Skip to main content

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Overview of attention for article published in BMC Cancer, September 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
27 Mendeley